RESEARCH STAFF Sample Clauses

RESEARCH STAFF. Subject to clauses 6.2 and 9.2, following consultation with the Institute, the HSP may withdraw or exclude Research Staff from the Premises. In the event of an emergency or adverse situation, the HSP may determine at its absolute discretion to withdraw, exclude or refuse to admit Research Staff to a part of or all of the Premises. If the HSP makes a determination in accordance with this clause, the HSP’s liaison officer will endeavour to promptly notify the Institute of that determination. In relation to Research Staff accessing the Premises to conduct Research, the Institute will take reasonable steps to ensure that: Each of the Research Staff have a level of preparation which is sufficient to meet the level of competence required for that aspect of the Research they will be undertaking; Research Staff who provide care to Research Participants in accordance with an approved Research Protocol are, where applicable, registered with the relevant Professional Registration Board, or, if there is no relevant registration board, are eligible for membership of their professional association. If required by the HSP, the Institute will provide evidence of that registration or eligibility for membership on demand. Research Staff, through the Principal Investigator and Coordinating Principal Investigator, notify the HSP and the Reviewing HREC of any required safety reporting (including Serious Adverse Events) that occur during the course of the Research, in accordance with the Protocol, the relevant ethical and regulatory guidelines and with the applicable Policies. In relation to Research conducted by Research Staff on the Premises, the Parties will cooperate with the Reviewing HREC in investigating any Adverse Event (including Serious Adverse Event) arising out of or in connection with the Research. Either Party will notify the other Party as soon as reasonably practical if it becomes aware of: in respect of Research Staff: a relevant Professional Registration Board or association fining or reprimanding them or requiring the Research Staff member to provide an undertaking to be of good behaviour, or makes conditional, suspends or removes the registration or membership of the Research Staff or the registration or membership lapses; any investigation by a relevant Professional Registration Board or association is commenced against a Research Staff member; any charges or convictions for an offence punishable by imprisonment being made against a Research Staff member; ...
AutoNDA by SimpleDocs
RESEARCH STAFF. All individuals, excluding the Investigator, who will have access to the data obtained through this agreement. The Research Staff must be affiliated with the Receiving Institution.
RESEARCH STAFF. Each of BioChem and Oncogene shall, no later than fifteen (15) days following execution of this Agreement, appoint research team comprised of such number of suitably qualified Ph.D. scientists and other suitable qualified scientists and other personnel as may be needed and agreed to between the Parties from time to time each to achieve the goals of the Research Program, it being understood that over the term of this Agreement, each Party shall have contributed, in terms of out-of-pocket expenses incurred by the Parties and their Affiliates (including salaries and such other costs and expenses referred to in Section 3.1 hereof), approximately equally in connection with the performance of their obligations under the Research Program and this Agreement.
RESEARCH STAFF. Each of Sepracor and Oncogene shall, no later than fifteen (15) days following commencement of JSC function under this Agreement, appoint research teams comprised of such number of suitably qualified scientists and other personnel as may be determined by the JSC to be reasonably necessary in order to achieve the goals of the Research Program and Development Program, it being understood that, unless otherwise agreed in writing by the Parties, over the term of this Agreement, (a) each Party shall have contributed, in terms of out-of-pocket expenses incurred during the term of this Agreement by the Parties and their Affiliates (including salaries and such other costs and expenses referred to in Section 3.1 hereof), approximately equally in connection with the performance of their obligations under the Research Program and this Agreement, and (b) such contribution are estimated to total up to approximately $12 million (or approximately up to $6 million by each Party) for the initial three year period.

Related to RESEARCH STAFF

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Project Leaders Within [**] Business Days after the Effective Date, each Party will appoint (and provide written notice to the other Party of the identity of) a senior representative having a general understanding of biopharmaceutical discovery and development issues to act as its project leader under this Agreement (each, a “Project Leader”). The Project Leaders will serve as the contact point between the Parties with respect to the Research Program, and will be primarily responsible for: (a) facilitating the flow of information and otherwise promoting communication, coordination of the day-to-day work and collaboration between the Parties; (b) providing single point communication for seeking consensus internally within the respective Party’s organization; and (c) raising cross-Party or cross-functional disputes in a timely manner. The Project Leaders shall conduct regular telephone conferences as deemed necessary or appropriate, to exchange informal information regarding the progress of the Research Program. Each Party may change its designated Project Leader from time to time upon prior written notice to the other Party. Each Project Leader may designate a substitute to temporarily perform the functions of that Project Leader by prior written notice to the other Party.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!